|
summary: This preliminary study reported that fingolimod, a new tablet treatment for relapsing remitting MS, was safe and effective in reducing relapse rate and inflammation of the brain. A larger phase III study is required.
authors: O'Connor P, Comi G, Montalban X, Antel J, Radue EW, de Vera A, Pohlmann H, Kappos L; FTY720 D2201 Study Group
source: Neurology. 2009 Jan 6;72(1):73-9
weblink: click here
category: Clinical Trials and Therapeutics
related research news: click here
glossary:
Brain
Inflammation
Multiple sclerosis
Relapse
Relapsing/remitting MS
Sclerosis
|
